{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 46,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 32,
  "notes": "The slide highlights that QW dosing is better tolerated, specifically noting less rash and manageable side effects compared to QD dosing.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/25",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.36,
        "y": 0.74
      },
      "kind": "list",
      "text": "QW dosing was well tolerated at doses up to 250mg; Reversible retinopathy is a known MEK/ERK inhibitor class effect; Transient nausea/vomiting was manageable; Less rash reported at QW dosing; No Grade 3 or higher eye toxicity observed at 250mg QW RD; Adverse event profile and QW dosing supports combination strategies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bb222c9-c7d0-488a-8f01-3626fc1571f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.04,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "ERAS-007 exhibited an expected, reversible, manageable adverse event profile",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5961933a-0899-4373-bc4e-3400505bad0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.15,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: ASN007-101 study; as of the December 21, 2020, data cutoff",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bfe8edf-4bea-4800-892e-3754d983f7e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.185
      },
      "kind": "table",
      "text": "Treatment-Related Adverse Events table comparing QD and QW schedules across various organ classes and symptoms.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fe697e1-d7d5-4a83-ab69-0a4a5bac0723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ERAS-007 QW schedule was better tolerated than QD (TRAEs)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0a436ec-5605-4521-8840-7bdccdffb35f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "62c0c0b2-592d-48bf-ac68-fd95dc943847",
      "evidence": "table/data: Treatment-Related Adverse Events table comparing QD and QW schedules across various organ classes and symptoms.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 19,
      "beatId": "11d59d21-8e5a-4b4f-88a7-a353748a6229",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document highlights the promising results from preclinical and clinical trials for ERAS-007 and ERAS-601.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}